Alcon Inc. alleges that a copy of Simbrinza proposed by Padagis Israel Pharmaceuticals Ltd. infringes two patents for the eye drops, which relieve eye pressure by using a combination of two medications to reduce the amount of fluid in the eye.
Fribourg, Switzerland-based Alcon filed the complaint Oct. 27, and it was docketed Oct. 28 in the US District Court for the District of New Jersey.
The patents both cover the drug’s pharmaceutical composition and expire in June and October 2030. They’re the only two patents listed for Simbrinza in the US Food and Drug Administration’s registry of approved ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.